Minerva Neurosciences, Inc.
NERV · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1 | $0 | $0 | $0 |
| Gross Profit | -$1 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $925 | $1,298 | $1,362 | $1,983 |
| G&A Expenses | $0 | $2,076 | $2,540 | $2,539 |
| SG&A Expenses | $1,918 | $2,076 | $2,540 | $2,539 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2,843 | $3,374 | $3,903 | $4,522 |
| Operating Income | -$2,844 | -$3,374 | -$3,903 | -$4,522 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $100 | $116 | $150 | $250 |
| Pre-Tax Income | -$2,744 | -$3,259 | -$3,753 | -$4,272 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2,744 | -$3,259 | -$3,753 | -$4,272 |
| % Margin | – | – | – | – |
| EPS | -0.36 | -0.43 | -0.5 | -0.56 |
| % Growth | 16.3% | 14% | 10.7% | – |
| EPS Diluted | -0.36 | -0.43 | -0.5 | -0.56 |
| Weighted Avg Shares Out | 7,569 | 7,569 | 7,569 | 7,569 |
| Weighted Avg Shares Out Dil | 7,569 | 7,569 | 7,569 | 7,569 |
| Supplemental Information | – | – | – | – |
| Interest Income | $107 | $137 | $158 | $240 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$2,743 | -$3,257 | -$3,752 | -$4,271 |
| % Margin | – | – | – | – |